Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Cash & Equivalents (2019 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Cash & Equivalents for 7 consecutive years, with $752.5 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 76.39% to $752.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $752.5 million through Dec 2025, up 76.39% year-over-year, with the annual reading at $752.5 million for FY2025, 76.39% up from the prior year.
  • Cash & Equivalents hit $752.5 million in Q4 2025 for Harmony Biosciences Holdings, up from $647.0 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $752.5 million in Q4 2025 to a low of $141.2 million in Q1 2021.
  • Historically, Cash & Equivalents has averaged $339.8 million across 5 years, with a median of $311.8 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: tumbled 31.43% in 2021 and later soared 82.98% in 2022.
  • Year by year, Cash & Equivalents stood at $156.8 million in 2021, then surged by 82.98% to $286.9 million in 2022, then rose by 8.64% to $311.7 million in 2023, then soared by 36.88% to $426.6 million in 2024, then surged by 76.39% to $752.5 million in 2025.
  • Business Quant data shows Cash & Equivalents for HRMY at $752.5 million in Q4 2025, $647.0 million in Q3 2025, and $427.7 million in Q2 2025.